Index to Volume 11 The index to Volume 11 is composed of three parts: a subject Clinical Pharmacy, as well as selected letters and news reports. index, an author index, and an advertising index. The subject index also notes all regular columns and, under the The subject index is made up mainly of terms constructed by respective column headings, the titles of items in the “News,” International Pharmaceutical Abstracts. The IPA index is an alpha- “Therapy Consultation,” “Letters,” “Editorials,” and “Book Re- betical, open-ended, controlled-vocabulary index that makes use views” sections. The subject index also contains, under the head- of standardized headings. (The primary index terms for each ing “Correction Notices,” the title and issue of publication of article are listed routinely in Clinical Pharmacy as “index terms” items for which corrections were printed, as well as the page after abstracts.) IPA covers all authored papers and editorials in numbers on which the corrections appear. Issue Pages Issue Pages January 1-92 July 571-656 February 93-204 August 657-742 March 205-280 September 743-822 April 281-374 October 823-904 May 375-454 November 905-988 June 455-570 December 989-1052 Subject Index A provals, 467 al dialysis, 1030 Aminoglycosides; intraperitoneal; absorption, CAPD, phenobarbital and ethosuximide; clearance, peritone- 246 al dialysis, 1030 Absorption Aminophylline Antidepressants anti-infective agents; intraperitoneal, CAPD, 246 availability; liquid, enteral administration, 428 depression; therapy, geriatrics, 96 metoclopramide hydrochloride; peritoneal dialysis, use; evaluation, criteria, 1033 fluvoxamine; therapy, review, 930 174 Amphotericin B paroxetine; therapy, review, 930 Acetaminophen; fever; therapy, pediatrics, review, candidiasis; therapy, burns, infant, 883 sertraline hydrochloride; FDA approvals, 381; thera- 1005 use; evaluation, bladder irrigation, criteria, 809 py, review, 930 Acquired immunodeficiency syndrome Anabolic agents; steroids; hyperfibrinogenemia thera- Antidotes didanosine; therapy, FDA approvals, 4 py, 968 charcoal activated and methylene blue; therapy, dap- 566C80; P. carinii pneumonia, treatment IND, FDA Analgesics and antipyretics sone toxicity, 800 approvals, 99 acetaminophen; fever therapy, pediatrics, review, methylene blue and charcoal activated; therapy, dap- foscarnet sodium; cytomegalic inclusion disease ther- 1005 sone toxicity, 800 apy, FDA approvals, 4 aspirin; fever therapy, pediatrics, review, 1005 Antiemetics ganciclovir; cytomegalic inclusion disease therapy, fentanyl; adverse reactions, transdermal patches, 222; metoclopramide hydrochloride; pharmacokinetics, liver toxicity, 432 transdermal patches, 22 CAPD, 174 zidovudine; therapy, DUE criteria, 63 ibuprofen; fever therapy, pediatrics, review, 1005 ondansetron hydrochloride; pharmacokinetics, thera- Adenosine; use; evaluation, criteria, 727 morphine sulfate; Baxter Infusor, PCA, postoperative py, cisplatin toxicity, 1026 Administration; Food and Drug Administration; proce- pain therapy, 342; intrathecal and i.v. PCA vs. PCA scopolamine; transdermal patches, hyperemesis grav- dures, changes, new-drug approvals, 574 alone, postoperative pain, 958; toxicity, muscle idarum therapy, 830 Adolescents spasticity, midazolam therapy, 57 Antifungals antihistamines; DUE criteria, therapy, extrapyrami- pain; protocols, therapy, 309, 391 amphotericin B; bladder irrigation, DUE criteria, 809; dal side effects, 553 Anemia; dapsone; hemolytic, toxicity, therapy, 800 candidiasis therapy, burns, infant, 883 antiparkinson agents; DUE criteria, therapy, extrapy- Anesthetics; toxicity; nausea and vomiting, abdominal fluconazole; candidiasis therapy, lack, burns, infant, ramidal side effects, 553 surgery, 965 883 benzodiazepines; DUE criteria, therapy, extrapyrami- Anesthetics, local toxicity; endocrine disorders, HIV infections, therapy, dal side effects, 553 lidocaine, combination, prilocaine; pain therapy, s.c. 705 parasympatholytic agents; DUE criteria, therapy, ex- injection sites, 347 Antihistamines trapyramidal side effects, 553 pain; protocols, therapy, 391 astemizole; toxicity, cardiovascular, labeling, warn- Adrenergic agents, see Sympathomimetic agents Angiotensin-converting enzyme inhibitors; labeling; ings, 825 Adverse drug reactions report form, 85, 649 warnings, risks, pregnancy, 467 diphenhydramine hydrochloride; therapy, fentanyl Advertising Index, 92, 204, 280, 374, 454, 570, 656, 742, Antiarrhythmic drugs, see Cardiac drugs adverse reactions, 222 822, 904, 988, 1042 Anti-infective agents drug use; evaluations, criteria, therapy, extrapyrami- Aerosols; § agonists; regular vs. as-needed, asthma dosage schedules; therapy, postantibiotic effect, 876 dal side effects, 553 therapy, 877 566C80; P. carinii pneumonia, treatment IND, FDA terfenadine; toxicity, cardiovascular, labeling, warn- Age; patients; home parenteral nutrition therapy, toxici- approvals, 99 ings, 825 ty, 543 surgery; prophylaxis, ASHP protocols, 483 Anti-inflammatory agents Agency for Health Care Policy and Research; proto- toxicity; endocrine disorders, HIV infections, therapy, nabumetone; FDA approvals, 381 cols; pain therapy, 309, 391 705; postantibiotic effect, factors, 865 nonsteroidal; toxicity, ulcers, therapy, review, 690 AIDS, see Acquired immunodeficiency syndrome Antibiotics oxaprozin; nonsteroidal, therapy, 591 Alcohols, cetyl; combination, colfosceril palmitate, dosage schedules; therapy, postantibiotic effect, 876 Antilipemic agents tyloxapol; adult respiratory distress syndrome thera- mechanism of action; postantibiotic effect, 865 hyperfibrinogenemia; therapy, 968 py, neonate, 880; use evaluation criteria, 355 toxicity; endocrine disorders, HIV infections, therapy, pravastatin sodium; FDA approvals, 99; hypercholes- Aldesleukin; marketing; FDA approvals, 669 705 terolemia therapy, review, 677 Allergies; fentanyl; diffuse rash, transdermal patches, vancomycin; intraperitoneal, absorption, CAPD, 246 simvastatin; FDA approvals, 290 92? Antibodies; monoclonal; antiendotoxin, DUE criteria, Antineoplastic agents Aluminum; blood levels; sucralfate toxicity, deferoxa- 257; sepsis therapy, 223; sepsis therapy, criteria, 255 aldesleukin; FDA approvals, 669 mine therapy, 636 Anticoagulants cisplatin; toxicity, ondansetron therapy, pharmacoki- Amantadine; hyperprolactinemia; therapy, psycho- heparin; vs. sodium chloride, i.v. lock flushing, 797 netics, 1026 tropic toxicity, 851 ticlopidine hydrochloride; FDA approvals, 99 finasteride; FDA approvals, 825 American Society of Hospital Pharmacists; protocols; toxicity; hemorrhage, dental surgery, 857 idarubicin; acute nonlymphocytic leukemia therapy, antimicrobial prophylaxis, surgery, 483; globulin im- warfarin sodium; interactions, tetracycline, potentia- 152 mune, i.v. therapy, 117 tion, prothrombin time, 806; toxicity, intramural he- leukemia; acute, adult, therapy, review, 767 Amino acids matoma of the small intestine, 632 taxol; treatment IND, FDA approvals, 912 choline; cognition disorders therapy, FDA disapprov- Anticonvulsants Antiparkinson agents; drug use; evaluation, criteria, als, 467 eclampsia; and preeclampsia therapy, 236 therapy, extrapyramidal side effects, 553 marketing; cognition disorders therapy, FDA disap- ethosuximide and phenobarbital; clearance, peritone- Vol 11 Dec 1992 Clinical Pharmacy 1043 Annual Index Antivirals Edition, 897 Clinical Pharmacy didanosine; AIDS therapy, FDA approvals, 4; DUE The Biochemical Basis of Neuropharmacology, Sixth Edi- acknowledgment to reviewers—October 1, 1991, to criteria, 885 tion, 655 September 30, 1992, 1032 foscarnet sodium; cytomegalic inclusion disease ther- Clinical Immunotoxicology, 900 instructions for submitting computer disks with re- apy, AIDS, FDA approvals, 4 Combined Modality Cancer Therapy: Radiation and Infu vised manuscripts, 62 ganciclovir; liver toxicity, cytomegalic inclusion dis- sional Chemotherapy, 565 procedure for submission of manuscripts to journals ease therapy, AIDS, 432 Data Collection Forms in Clinical Trials, 373 published by the American Society of Hospital toxicity; endocrine disorders, HIV infections, therapy, Drugs in Gastroenterology, 565 Pharmacists, 60 705 Guide to Clinical Trials, 277 Clinical studies zalcitabine; AIDS buyers groups, FDA actions, 385; Handbook of Basic Pharmacokinetics including Clinical dobutamine; congestive heart failure, long-term ther- marketing, FDA approvals, accelerated drug re- Applications, Fourth Edition, 901 apy, 618 view policy, 747 Manual of Antibiotics and Infectious Diseases, Seventh pravastatin sodium; hypercholesterolemia therapy, zidovudine; DUE criteria, 63 Edition, 742 review, 677 zidovudine and zalcitabine; combined therapy, HIV Neoplastic Diseases: Fundamentals of Clinical Oncology, Cognition disorders; therapy; amino acids, vitamins, infections, 747 901 marketing, FDA disapprovals, 467 Anxiolytics, sedatives and hypnotics; triazolam; label- Pharmacokinetics and Pharmacodynamics, Volume 3: Pep Colfosceril palmitate; combination, alcohols, cetyl, ing changes, package inserts, FDA approvals, 467; tides, Peptoids, and Proteins, 277 tyloxapol; adult respiratory distress syndrome thera- product withdrawal, United Kingdom, 9 Books Received, 198, 374, 454, 570, 655, 742, 904, 1042 py, neonate, 880; use ev aluation criteria, 355 Arrhythmia; therapy; toxicity, review, 714 Bromocriptine; hyperprolactinemia; therapy, psycho- Collagen; hemorrhage; microcrystalline, prophylaxis, Arthritis tropic toxicity, 851 dental surgery, anticoagulant toxicity, 857 nabumetone; rheumatoid, therapy, FDA approvals, Burns Combined therapy 381 amphotericin B; candidiasis therapy, infant, 883 acetaminophen and aspirin; fever, pediatrics, review, oxaprozin; rheumatoid, therapy, 591 fluconazole; candidiasis therapy, lack, infant, 883 1005 ASHP Commission on Therapeutics; protocols; antimi- aspirin and acetaminophen; fever, pediatrics, review, crobial prophylaxis, surgery, 483; i.v. globulin im- Cc 1005 mune, 117 zalcitabine and zidovudine; HIV infections, FDA ap- Asians; Koreans; phenylpropanolamine, toxicity, hy- provals, 747 pertension, lack, 168 zidovudine and zalcitabine; HIV infections, FDA ap- Aspirin Calcium antagonists provals, 747 eclampsia; and preeclampsia therapy, 236 hyperfibrinogenemia; therapy, 968 Commentaries, 350, 549, 714, 797, 876, 968 fever; therapy, pediatrics, review, 1005 new drugs; advantages, 549 Complexes Astemizole; toxicity; cardiovascular, labeling, warn- nimodipine; cerebrovascular ischemia therapy, 350 Haemophilus b oligosaccharide conjugate vaccines; ings, 825 verapamil hydrochloride; pharmacokinetics, intact equivalency, immunogenicity, pediatrics, 332 Asthma capsules vs. sprinkled on food, 539 Haemophilus b polysaccharide conjugate vaccines; B agonists; therapy, aerosols, dosage schedules, 877 Calcium regulators; pamidronate disodium; hypercal- equivalency, immunogenicity, pediatrics, 332 sympathomimetic agents; § agonists, therapy, contro- cemia therapy, FDA approvals, 220 Compliance; patients; calcium antagonists therapy, 549 versies, 13 Cancer, see Antineoplastic agents Concentration Atracurium besylate; use; evaluation, criteria, 435 Cancer drugs, see Antineoplastic agents antibiotics; postantibiotic effect, 865 Availability, drugs, see Drugs, availability Candidiasis ceftriaxone; i.m., pharmacokinetics, toxicity, pediat- Azithromycin amphotericin B; therapy, burns, infant, 883 rics, 961 marketing; delay, Pfizer, 218; FDA approvals, 98 fluconazole; therapy, lack, burns, infant, 883 globulin immune; injections, administration rate, tox- pharmacology, 137 Capsules; verapamil hydrochloride; intact vs. sprinkled icity, 1022; reconstitution, dextrose vs. water for on food, equivalency, pharmacokinetics, 539 injection, 628 Carbamazepine; concomitant therapy, 632 Control, quality; zalcitabine; problems, AIDS buyers Carcinoma; aldesleukin; renal cell, therapy, FDA ap- groups, 385 provals, 669 Coronary disease; tests, laboratory; cholesterol and Cardiac drugs HDL monitoring, 378 Bacterial infections adenosine; DUE criteria, Correction Notices, 14, 308, 585, 750, 829 antibodies; antiendotoxin monoclonal, therapy, antiarrhythmic agents; therapy, toxicity, review, 714 Advances in the treatment of unstable angina pectoris antiendotoxin monoclonal, therapy, criteria, dobutamine; congestive heart failure, long-term ther- (Nov '991, Therapy Review), 14 antiendotoxin monoclonal, therapy, DUE criteria, apy, 618 American Academy of Pediatrics issues recommenda- 257 flecainide; interactions, implanted cardiac devices, 48 tions on treatment of Lyme disease (Oct 1991, anti-infective agents; prophylaxis, surgery, ASHP moricizine; interactions, implanted cardiac devices, News), 14 protocols, 483 48 Clarithromycin and azithromycin: New macrolide cefpodoxime proxetil; bacterial, therapy, FDA ap- Cefazolin sodium; toxicity; seizures, intraventricular antibiotics (Feb 1992, Drug Review), 308 provals, 999 injections, 104 Parenteral nutrition in pediatric patients (May 1988, cefprozil; therapy, FDA approvals, 295 Cefpodoxime proxetil; marketing; FDA approvals, 999 Therapy Review), 750 lomefloxacin hydrochloride; therapy, FDA approvals, Cefprozil; marketing; FDA approvals, 295 Retreatment with digoxin immune Fab (Nov 1991, 458 Ceftriaxone; reconstitution; i.m., pharmacokinetics and Letters), 14 temafloxacin hydrochloride; therapy, FDA approvals, toxicity, pediatrics, 961 Review of 1991 shows 30 new drugs, several impor- 381 Cellulose; hemorrhage; prophylaxis, dental surgery, tant biologics cleared for marketing (Mar 1992, Barbiturates; pain; protocols, therapy, 391 anticoagulant toxicity, 857 News), 585 Basal ganglia diseases; psychotherapeutic agents; toxic- Central nervous system drugs; cognition activators; Table of contents (Aug 1992), 829 ity, therapy, DUE criteria, 553 FDA disapprovals, 467 Cost Benzodiazepine antagonists; flumazenil; FDA approv- Cephalosporins Haemophilus b oligosaccharide conjugate vaccines; im- als, 287 cefazolin sodium; toxicity, seizures, intraventricular munization, pediatrics, 332 Benzodiazepines injections, 104 Haemophilus b polysaccharide conjugate vaccines; im- drug use; evaluation, criteria, therapy, extrapyrami- cefpodoxime proxetil; FDA approvals, 999 munization, pediatrics, 332 dal side effects, 553 cefprozil; FDA approvals, 295 zalcitabine; therapy, 747 overdose; toxicity, flumazenil therapy, 287 ceftriaxone; concentrated, pharmacokinetics, toxicity, CP Continuing Education, 77, 189, 261, 442, 559, 640, pain; protocols, therapy, 391 pediatrics, 961 731, 811, 892, 976, 1039 Beractant; use; evaluation, criteria, 357 intraperitoneal; absorption, CAPD, 246 Creams; lidocaine, combination, prilocaine; anesthesia, Bioavailability, see Drugs, availability Cerebral ischemia; nimodipine; therapy, 350 pain, s.c. injection sites, 347 Biologicals; approvals; FDA, 1991, 208 Cerebrovascular disorders Current Literature, 87, 197, 273, 368, 448, 562, 65 Blood levels nimodipine; ischemic stroke therapy, 350 819, 895, 978, 1040 aluminum; sucralfate toxicity, deferoxamine therapy ticlopidine hydrochloride; prophylaxis, FDA approv- Cytomegalic inclusion disease 636 als, 99; therapy, review, 603 foscarnet sodium; therapy, AIDS, FDA approvals, 4 ceftriaxone; i.m., concentrated, pediatrics, 961 Charcoal activated; and methylene blue; therapy, dap- ganciclovir; therapy, liver toxicity, AIDS, 432 cholesterol; and HDL monitoring, coronary disease sone toxicity, 800 Cytotoxic agents, see Antineoplastic agents 378 Cholelitholytic agents; ursodiol; pruritus therapy, bili- ciprofloxacin; and milk levels, 352 ary cirrhosis, 672 ethosuximide and phenobarbital; decreased, perito- Cholesterol; tests, laboratory; and HDL monitoring, D neal dialysis, 1030 coronary disease, 378 fentanyl; transdermal patches, pain therapy, 22 Choline; marketing; cognition disorders therapy, FDA ondansetron hydrochloride; pharmacokinetics, thera- disapprovals, 467 Dapsone; toxicity; hemolytic anemia, methemoglobin- py, cisplatin toxicity, 1026 Ciprofloxacin hydrochloride; body distribution; blood emia, therapy, 800 phenobarbital and ethosuximide; decreased, perito- and milk levels, 352 ddl, see Didanosine neal dialysis, 1030 Cisplatin; toxicity; ondansetron therapy, pharmacoki- Deferoxamine mesylate; therapy; aluminum overload, theophylline; aminophylline availability, enteral ad- netics, 1026 sucralfate toxicity, CAPD, 636 ministration, 428 Clarithromycin Depression Book Reviews, 92, 277, 373, 565, 655, 742, 897, marketing; FDA approvals, 98 serotonin reuptake inhibitors; therapy, review, 930 Advances in Pain Research and Therapy, Volume 18: The pharmacology, 137 sertraline hydrochloride; therapy, FDA approvals, Design of Analgesic Clinical Trials, 92 Clearance, see Excretion 381 Applied Therapeutics: The Clinical Use of Drugs, Fifth therapy; geriatrics, 96 1044 Clinical Pharmacy Vol 11 Dec 1992 Annual Index Devices al dialysis, 1030 clarithromycin, 137 Baxter Infusor; morphine PCA, postoperative pain pravastatin sodium, 99; hypercholesterolemia thera- devices and antiarrhythmic agents; cardiac implants, therapy, 342 py, review, 677 impaired functioning, 48 implants; cardiac, interactions, antiarrhythmic agents, quinapril hydrochloride, 220 food and verapamil hydrochloride; equivalency, in- 48 serotonin reuptake inhibitors; depression therapy, re- tact capsules vs. sprinkled, 539 metrology; cups, spoons, droppers, drug overdose, view, 930 lomefloxacin hydrochloride; review, 753 220 sertraline hydrochloride, 381 ondansetron hydrochloride and cisplatin; pharmaco- Dextrose; comparison, water for injection; globulin im- simvastatin, 290 kinetics, 1026 mune reconstitution, toxicity, 628 skeletal muscle relaxants; DUE criteria, 435 serotonin reuptake inhibitors; depression therapy, re- Diabetes mellitus sumatriptan; DUE criteria, 972 view, 930 electrolytes, combination, polyethylene glycol; gastric sumatriptan succinate; therapy, review, 919 sucralfate and tests, laboratory; occult blood, interfer- lavage, protocols, 751 temafloxacin hydrochloride, 381; review, 753 ence, 625 metoclopramide hydrochloride; pharmacokinetics, theophylline; DUE criteria, 1033 temafloxacin hydrochloride; review, 753 CAPD, 174 ticlopidine hydrochloride, 99; review, 603 tests, laboratory and sucralfate; occult blood, interfer- Dialysis; peritoneal; clearance, ethosuximide and phe- ursodiol; pruritus therapy, biliary cirrhosis, 672 ence, 625 nobarbital, 1030; continuous ambulatory, anti-infec- zalcitabine, 747 tetracycline hydrochloride and warfarin sodium; po- tive agents absorption, 246; metoclopramide pharma- zidovudine; DUE criteria, 63 tentiation, prothrombin time, 806 cokinetics, 174; sucralfate, toxicity, aluminum over- Dosage forms verapamil hydrochloride and food; equivalency, in- load, 636 drug administration systems; measuring cups, tact capsules vs. sprinkled, 539 Diazepam; eclampsia; and preeclampsia therapy, 236 spoons, droppers, overdose, 220 warfarin sodium end tetracycline hydrochloride; po- Didanosine fentanyl; transdermal patches, adverse reactions, 222; tentiation, prothrombin time, 806 marketing; FDA approvals, 4 transdermal patches, pain therapy, 22 Drug Reaction Alerts, 87, 197, 273, 368, 448, 562, 652, use; evaluation, criteria, 885 Dosage schedules 735, 819, 895, 978, 1040 Diluents; lidocaine; ceftriaxone, i.m., reconstitution, pe- 6 agonists; aerosols, regular vs. as-needed, asthma Drugs diatrics, 961 therapy, 877 new; marketing, FDA approvals, 1991, 208 Diphenhydramine hydrochloride; allergies; therapy, antibiotics; postantibiotic effect, 865; therapy, postan- reconstitution; ceftriaxone, i.m., pharmacokinetics, fentanyl adverse reactions, 222 tibiotic effect, 876 toxicity, pediatrics, 961; globulin immune, dextrose Diphtheria and tetanus toxoids and pertussis vac- anti-infective agents; prophylaxis, surgery, ASHP vs. water for injection, 628 cines; marketing; FDA approvals, 290 protocols, 483; therapy, postantibiotic effect, 876 selection; antimicrobial prophylaxis, surgery, ASHP Diuretics; hydrochlorothiazide; hypertension therapy, calcium antagonists; therapy, 549 protocols, 483 phenylpropanolamine effects, lack, 168 dobutamine; congestive heart failure, long-term ther- Drugs, adverse reactions, see Toxicity Dobutamine; heart failure; congestive, long-term thera- apy, 618 Drugs, availability; aminophylline; liquid, enteral ad- py, 618 nutrition; parenteral, chronic home therapy, toxicity, ministration, 428 Dosage 543 Drugs, body distribution adenosine; DUE criteria, 727 oxaprozin, 591 ciprofloxacin hydrochloride; blood and milk levels, alcohols, cetyl, combination, colfosceril palmitate, triazolam; labeling changes, FDA approvals, 467 352 tyloxapol; DUE criteria, 355 Doxacurium chloride; use; evaluation, criteria, 435 metoclopramide hydrochloride; peritoneal dialysis, aldesleukin, 669 Doxazosin mesylate; pharmacology; review, 415 174 aminophylline; DUE criteria, 1033 Drug administration Drugs, investigational amphotericin B; DUE criteria, 809 alcohols, cetyl, combination, colfosceril palmitate, investigational new drugs; 566C80, P. carinii pneumo- analgesics and antipyretics; fever therapy, pediatrics, tyloxapol; intratracheal, adult respiratory distress nia, protocols, 99; taxol, ovarian neoplasms thera- review, 1005 syndrome, neonate, 880 py, protocols, 912; zalcitabine, FDA actions, pre- antibodies; monoclonal antiendotoxin, DUE criteria, y-interferon; chronic granulomatous disease therapy, marketing access, 385 257 834 new-drug applications; approvals, changes, FDA pro- antihistamines; DUE criteria, therapy, extrapyrami- interferon gamma-1b; chronic granulomatous disease cessing, 574 dal side effects, 553 therapy, 834 Drug use anti-infective agents; intraperitoneal, absorption, serotonin reuptake inhibitors; depression therapy, re- evaluation; adenosine, criteria, 727; aminophylline, CAPD, 246 view, 930 theophylline, criteria, 1033; amphotericin B, blad- antiparkinson agents; DUE criteria, therapy, extrapy- verapamil hydrochloride; equivalency, intact cap- der irrigation, criteria, 809; antiendotoxin mono- ramidal side effects, 553 sules vs. sprinkled on food, 539 clonal antibodies, criteria 7; beractant, criteria, azithromycin, 98, 137 Drug administration rate; globulin immune; i.v. infu- 357; didanosine, criteria, 885; Exosurf Neonatal, cri- benzodiazepines; DUE criteria, therapy, extrapyrami- sion, concentrated, toxicity, 1022 teria, 355; omeprazole, criteria, 177; skeletal muscle dal side effects, 553 Drug administration routes relaxants, criteria, 435; sumatriptan criteria, 972; beractant; DUE criteria, 357 B agonists; regular vs. as-needed, asthma, 877 therapy, extrapyramidal side effects, 553; zidovudi- cefpodoxime proxetil, 999 aminophylline; enteral administration, availability, ne, criteria, 63 cefprozil, 295 428 fentanyl; diffuse rash, transdermal patches, 222 cisplatin; high, toxicity, ondansetron therapy, 1026 anti-infective agents; prophylaxis, surgery, ASHP DUE Criteria, 63, 177, 257, 355, 435, 553, 727, 809, 885, clarithromycin, 98, 137 protocols, 483 972, 1033 didanosine, 4; DUE criteria, 885 cefazolin sodium; intraventricular, toxicity, seizures, adenosine, 727 diphtheria and tetanus toxoids and pertussis vac- 104 , agents for extrapyramidal adverse effects, 553 cines; immunization, pediatrics, 290 deferoxamine mesylate; intraperitoneal, i.v., alumi- amphotericin B bladder irrigation, 809 dobutamine; congestive heart failure, long-term ther- num overload therapy, 636 antiendotoxin monoclonal antibodies (HA-1A and apy, 618 fentanyl; transdermal patches, pain therapy, 22 E5), 257 doxazosin mesylate, 415 intraperitoneal; anti-infective agents, absorption, beractant (Survanta), 357 ethosuximide and phenobarbital; clearance, peritone- CAPD, 246 colfosceril (Exosurf Neonatal), 355 al dialysis, 1030 mesalamine; rectal, inflammatory bowel disease ther- didanosine, 885 felodipine, 9 apy, 514 omeprazole, 177 fentanyl; adverse reactions, transdermal patches, 222 methotrexate; intramuscular, ectopic pregnancy ther- pancuronium bromide, vecuronium bromide, atra- finasteride, 825 apy, 529 curium besylate, tubocurarine chloride, metocurine flumazenil, 287 metoclopramide hydrochloride; i.p. vs. i.v. oral, phar- iodide, pipecuronium bromide, and doxacurium foscarnet sodium, 4 macokinetics, CAPD, 174 chloride, 435 Haemophilus b oligosaccharide conjugate vaccines; im- morphine sulfate; intrathecal and i.v. PCA vs. PCA sumatriptan, 972 munization, pediatrics, 332 alone, postoperative pain therapy, 958 theophylline (aminophylline), 1033 Haemophilus b polysaccharide conjugate vaccines; im- olsalazine sodium; oral, inflammatory bowel disease zidovudine, 63 munization, pediatrics, 332 therapy, 514 idarubicin, 152 roentgenographic agents; ionic, epidural, toxicity, in- E y-interferon; review, 834 advertent intrathecal injection, 105 interferon gamma-1b; review, 834 scopolamine; transdermal patches, hyperemesis grav- lactase; lactose intolerance, reduced symptoms, 533 idarum therapy, 830 lomefloxacin hydrochloride, 458; review, 753 Drug administration sites Eclampsia; therapy, 236 morphine sulfate; Baxter Infusor, PCA, postoperative fentanyl; transdermal patches, adverse reactions, 222 Editorial; Who should receive antiendotoxin mono- pain therapy, 342 lidocaine, combination, prilocaine; anesthesia, pain, clonal antibody therapy? 255 nabumetone, 381 s.c. injections, 347 Electrolytes; combination, polyethylene glycol; gastric omeprazole; ulcers, peptic esophagitis, DUE criteria, Drug administration systems lavage, diabetes mellitus, protocols, 751 177 Baxter Infusor; morphine PCA, postoperative pain Endocrine diseases; therapy; HIV infections related, overdose; benzodiazepines, flumazenil therapy, 287; therapy, 342 705 dapsone, toxicity, hemolytic anemia, methemoglo- devices; measuring cups, spoons, droppers, overdose, Enzymes; lactase; lactose intolerance, reduced symp- binemia, 800; measuring cups, spoons, droppers, 220 toms, 533 toxicity, 220 Drug interactions Epidemiology; leukemia; adult acute, therapy, review, oxaprozin, 591 antiarrhythmic agents and devices; cardiac implants, 767 pamidronate disodium, 220 impaired functioning, 48 Epilepsy parasympatholytic agents; DUE criteria, therapy, ex- azithromycin, 137 ethosuximide and phenobarbital ; absence, clearance, trapyramidal side effects, 553 cisplatin and ondansetron hydrochloride; pharmaco- peritoneal dialysis, 1030 phenobarbital and ethosuximide; clearance, peritone- kinetics, 1026 phenobarbital and ethosuximide; absence, clearance, Vol 11 Dec 1992 Clinical Pharmacy 1045 Annual Index peritoneal dialysis, 1030 misoprostol; ulcer therapy, NSAID toxicity, review, felodipine; FDA approvals, 9 Equivalency 690 quinapril hydrochloride; marketing, FDA approvals, Haemophilus b oligosaccharide conjugate vaccines; im- olsalazine sodium; inflammatory bowel disease ther- 220 munogenicity, pediatrics, 332 apy, 514 Haemophilus b polysaccharide conjugate vaccines; im- omeprazole; DUE criteria, 177; ulcer therapy, NSAID munogenicity, pediatrics, 332 toxicity, review, 690 verapamil hydrochloride; pharmacokinetics, intact sucralfate; interference, occult blood tests, 625; toxici- capsules vs. sprinkled on food, 539 ty, aluminum overload, deferoxamine therapy, Equivalency, generic; globulin immune; formulary se- CAPD, 636 Ibuprofen; fever; therapy, pediatrics, review, 1005 lection, ASHP protocols, 117 Gastrointestinal hemorrhage; § blockers; prophylaxis, Idarubicin; leukemia; nonlymphocytic, acute, therapy, Errors, medication; dosage; measuring devices, 220 cirrhosis, esophageal varices, 337 152 Erythromycin; gastroparesis; therapy, effects, motilin, Gastroparesis; erythromycin; therapy, 917 Immunization 917 Gelatin; sponges; hemorrhage prophylaxis, dental sur- diphtheria and tetanus toxoids and pertussis; vac- Esophageal and gastric varices; fs blockers; gastrointes- gery, anticoagulant toxicity, 857 cines, FDA approvals, 290 tinal hemorrhage prophylaxis, 337 Geriatrics Haemophilus influenzae; conjugate vaccines, immuno- Esophagitis; omeprazole; peptic, therapy, DUE criteria, depression; therapy, 96 genicity, pediatrics, 332 177 pain; therapy, protocols, 391 rabies; vaccines, human rabies immune globulin, 37 Ethosuximide; and phenobarbital; clearance, peritoneal Globulin immune Immunogenicity dialysis, 1030 reconstitution; dextrose vs. water for injection, toxici- Haemophilus b oligosaccharide conjugate vaccines; Excretion ty, 628 equivalency, pediatrics, 332 ethosuximide and phenobarbital; clearance, peritone- therapy; i.v., ASHP protocols, 117 Haemophilus b polysaccharide conjugate vaccines; al dialysis, 1030 toxicity; side effects, concentrated injections, 1022 equivalency, pediatrics, 332 metoclopramide hydrochloride; clearance, CAPD, Granulomatous disease Immunosuppressive agents; methotrexate; ectopic 174 y-interferon; chronic, therapy, 834 pregnancy therapy, 529 phenobarbital and ethosuximide; clearance, peritone- interferon gamma-1b; chronic, therapy, 834 Immunotherapy al dialysis, 1030 Guidelines, treatment, see Protocols globulin immune; i.v. therapy, ASHP protocols, 117; reconstitution, dextrose vs. water for injection, 628; FE H ttorxaincsiptlya, ntactoinocne,n t1r0a2t2e d injections, bone marrow y-interferon; chronic granulomatous disease, 834 interferon gamma-1b; chronic granulomatous dis- Felodipine; marketing; FDA approvals, 9 HA-1A ease, 834 Fentanyl see also Nebacumab nebacumab; sepsis, criteria, 255; sepsis, DUE criteria, adverse reactions; diffuse rash, transdermal patches, sepsis; antiendotoxin monoclonal antibodies, therapy, 257 999 223 sepsis; antiendotoxin monoclonal antibodies, 223 patches transdermal; pain therapy, 22 Haemophilus b oligosaccharide conjugate vaccines; Xomen-E5; sepsis, criteria, 255; sepsis, DUE criteria, Fever; analgesics and antipyretics; therapy, pediatrics, immunization; equivalency, immunogenicity, pediat- 257 review, 1005 rics, 332 Implants; heart; interactions, antiarrhythmic agents, 48 Finasteride; marketing; FDA approvals, 825 Haemophilus influenzae; immunization; conjugate vac- Inflammatory bowel disease 566C80; pneumonia; P. carinii, treatment IND, FDA ap- cines, immunogenicity, pediatrics, 332 mesalamine; therapy, 514 provals, 99 Headache; sumatriptan; therapy, DUE criteria, 972 olsalazine sodium; therapy, 514 Flecainide; interactions; implanted cardiac devices, 48 Health care; home; parenteral nutrition, toxicity, 543 Injections Fluconazole; candidiasis; therapy, lack, burns, infant, Heart failure; dobutamine; congestive, long-term thera- cefazolin sodium; intraventricular, toxicity, seizures, 883 py, 618 104 Flumazenil; marketing; FDA approvals, 287 Heavy metal antagonists; deferoxamine mesylate; thera- ceftriaxone; i.m., concentrated, pharmacokinetics and Fluvoxamine; depression; therapy, review, 930 py, aluminum overload, sucralfate toxicity, CAPD, 636 toxicity, pediatrics, 961 Food; interactions; verapamil, open vs. intact capsules, Hematoma; warfarin sodium; toxicity, intramural, dobutamine; intravenous, congestive heart failure, pharmacokinetics, 539 small intestine, 632 long-term therapy, 618 Food and Drug Administration (U.S.) Hemorrhage; anticoagulants; toxicity, dental surgery, globulin immune; concentrated, i.v. infusion rate, approvals; aldesleukin marketing, 669; azithromycin, 857 toxicity, 1022; reconstitution, dextrose vs. water for clarithromycin, marketing, 98; cefpodoxime mar- Hemostatics; therapy; anticoagulant toxicity, dental injection, 628; i.v. therapy, ASHP protocols, 117 keting, 999; cefprozil marketing, 295; didanosine, surgery, 857 heparin, comparison, sodium chloride; lock flushing, foscarnet, marketing, 4; DTP vaccines marketing, Heparin; flushes; toxicity, thrombocytopenia, thrombo- 'O7 290; felodipine marketing, 9; finasteride marketing, embolism, 797 morphine sulfate; intrathecal and i.v. PCA vs. PCA 825; flumazenil marketing, 287; lomefloxacin mar- HIV infections alone, postoperative pain, 958 keting, 458; nabumetone marketing, 381; new-drug didanosine; therapy, DUE criteria, 885 pamidronate disodium; marketing, FDA approvals, applications, changes, processing, 574; new drugs therapy; associated endocrine disorders, 705 220 and biologicals, 1991, 208; pamidronate, marketing, zalcitabine; therapy, Roche premarketing access pro- patient-controlled analgesia; morphine, Baxter Infu- 220; pravastatin, marketing, 99; quinapril, market- grams, 385 sor, postoperative pain therapy, 342 ing, 220; sertraline marketing, 381; simvastatin mar- zalcitabine and zidovudine; combined therapy, FDA roentgenographic agents; ionic, epidurai, toxicity, in- keting, 290; temafloxacin marketing, 381; ticlopi- approvals, 747 advertent intrathecal administration, 105 dine, marketing, 99; triazolam labeling changes, zidovudine and zalcitabine; combined therapy, FDA sodium chloride, comparison, heparin; lock flushing, package inserts, 467; zalcitabine, marketing, accel- approvals, 747 797 erated drug review policy, 747 Hoffmann-La Roche Pharmaceuticals; zalcitabine; in- subcutaneous; pain, lidocaine-prilocaine therapy, 347 azithromycin; actions, toxicity reports, marketing de- vestigationa! new drugs, premarketing access pro- Insomnia; triazolam; therapy, labeling, changes, pack- lay, 218 grams, 385 age inserts, FDA approvals, 467 cognition activators; disapprovals, marketing, 467 Hospitals; length of stay; nausea and vomiting, anes- y Interferon; granulomatous disease; chronic, therapy, 566C80; P. carinii pneumonia, treatment IND approv- thetics toxicity, surgery, 965 review, 834 als, 99 Hydrochlorothiazide; hypertension; phenylpropanol- Interferon gamma-1b; granulomatous disease; chronic, labeling; drug measuring devices, overdose, 220 amine effects, lack, 168 therapy, review, 834 regulations; astemizole, terfenadine, warning labels, Hyperalimentation, see Nutrition; parenteral Irrigating solutions; amphotericin B; bladder, urinary cardiovascular toxicity, 825; temafloxacin, toxicity, Hypercalcemia; pamidronate disodium; therapy, neo- anti-infectives, DUE criteria, 809 product withdrawal, 747 plasms, FDA approvals, 220 ttarxioalz;o ltarme;a tamcetnito nsI, NDto xaicpiptryo vraelpso,r ts9,1 2 9 Hypprearvcahsotlaetsint erosoldeimuima; therapy, FDA approvals, 99; K zalcitabine; actions, AIDS buyers groups, quality therapy, review, 677 problems, 385 simvastatin; therapy, FDA approvals, 290 Formularies; globulin immune; product selection Hyperemesis gravidarum; scopolamine; transdermal Kidney failure ASHP protocols, 117 patches, 830 metoclopramide hydrochloride; pharmacokinetics, Foscarnet sodium; marketing; FDA approvals, 4 Hyperfibrinogenemia; therapy, 968 CAPD, 174 Hyperprolactinemia; psychotherapeutic agents; toxici- sucralfate; toxicity, ?tuminum overload, deferoxam- G ty, therapy, 851 ine therapy, CAPD, 636 Hypertension doxazosin mesylate; therapy, review, 415 i felodipine; therapy, FDA approvals, 9 Ganciclovir; toxicity; liver, cytomegalic inclusion dis- phenylpropanolamine hydrochloride; toxicity, lack, ease therapy, AIDS, 432 168 Gastric lavage; electrolytes, combination, polyethylene quinapril hydrochloride; therapy, FDA approvals, Labeling glycol; diabetes mellitus, protocols, 751 220 angiotensin-converting enzyme inhibitors; warnings, Gastrointestinal drugs Hypotensive agents risks, pregnancy, 467 histamine H, antagonists; ulcer therapy, NSAID toxic- doxazosin mesylate; review, 415 astemizole; warnings, cardiovascular toxicity, 825 ity, review, 690 eclampsia; and preeclampsia therapy, devices; dosage measuring, overdose, 220 mesalamine; inflammatory bowel disease therapy, terfenadine; warnings, cardiovascular toxicity, 825 514 triazolam; changes, FDA approvals, 467 1046 Clinical Pharmacy Vol 11 Dec 1992 Annual Index Lactase; lactose intolerance; effects, reduced symptoms, peritoneal dialysis, 174 creased risk of fatal or near-fatal asthma, study 533 Metocurine iodide; use; evaluation, criteria, 435 shows, 458 , Lactation; ciprofloxacin hydrochloride; milk and blood Metrology; devices; dosage measuring, overdose poten- Lomefloxacin reaches U.S. market, 458 tial, 220 Nabumetone marketed for osteoarthritis, rheumatoid Lactose intolerance; lactase; effects, reduced symptoms, Midazolam hydrochloride; muscle spasticity; therapy, arthritis, 381 533 morphine toxicity, 57 New labeling and patient insert for triazolam ap- Letters, 13, 104, 222, 308, 386, 583, 674, 767 Migraine proved by FDA, 467 Asthma in children, 386 sumatriptan; therapy, DUE criteria, 972 News Briefs, 9, 103, 221, 296, 385, 467, 576, 670, 750, Beta-adrenergic agonists in asthma, 13 sumatriptan succinate; therapy, review, 919 829, 912, 1000 Danger of epidural use of ionic contrast media, 105 Misoprostol; ulcers; therapy, NSAID toxicity, review, Orai temafloxacin approved for U.S. market, 381 Diffuse rash associated with transdermal fentanyl, 690 Pamidronate released for management of hypercalce- 999 Monoamine oxidase inhibitors; depression; therapy, mia of malignancy, 220 Potential interaction between terfenadine and macro- geriatrics, 96 Pediatrics academy issues new guidelines for acellu- lide antibiotics, 675 Moricizine; interactions; implanted cardiac devices, 48 lar pertussis vaccine use, 576 Seizures after intraventricular cefazolin adminstra- Morphine sulfate Pfizer delays marketing azithromycin, 218 tion, 104 pain; postoperative, intrathecal and i.v. PCA vs. PCA, Pravastatin reaches U.S. market, 99 Topical capsaicin for osteoarthritis, 308 958 Quinapril marketed as antihyveriensive agent, 220 Use of cytomegalovirus immune globulin, 674 patient-controlled analgesia; Baxter Infusor, postop- Results of ISIS-3 published, 576 Use of succimer, 387 erative pain therapy, 342 Review of 1991 shows 30 new drugs, several impor- Use of surfactant products, 583 toxicity; muscle spasticity, midazolam therapy, 57 tant biologics cleared for marketing, 208 Value of transdermal fentanyl, 584 Mortality Sertraline cleared for marketing as antidepressant, Leukemia; therapy; acute, adult, review, 767 B agonists; regular vs. as-needed, asthma therapy, 877 381 Lidocaine antiarrhythmic agents; toxicity, 714 Tacrine made available under treatment IND proto- combination, prilocaine; anesthesia, pain, s.c. injec- Mouthwashes; tranexamic acid; hemorrhage prophy- col, 385 tion sites, 347 laxis, anticoagulant toxicity, dental surgery, 857 Talley to succeed Zellmer as editor of AJHP and Clin- diluents; ceftriaxone, reconstitution, concentrated, pe- Muscle spasticity; morphine sulfate; toxicity, midazo- ical Pharmacy, 750 diatrics, 961 lam therapy, 57 Terfenadine and astemizole pose cardiovascular risks Liver cirrhosis to certain patients, health professionals warned, 825 B b3l3o7c kers; gastrointestinal hemorrhage prophylaxis, N Thicrhdo lesHtMerGo-l CoreAd uctrieodnu,c t2a9s0e inhibitor marketed for ursodiol; biliary, pruritus therapy, 672 Three studies examine angiotensin-converting-en- Liver diseases; effects; astemizole, terfenadine toxicity, zyme-inhibitor prevention of heart failure, 999 825 Nabumetone; marketing; FDA approvals, 381 Ticlopidine approved for stroke prevention, 99 Lomefloxacin hydrochloride Nadolol; gastrointestinal hemorrhage; prophylaxis, cir- Treatment IND protocol announced for Pneumocystis marketing; FDA approvals, 458 rhosis, esophageal varices, 337 carinii pneumonia, 99 pharmacology; review, 753 Nausea Two macrolide antimicrobials approved for market- Lung diseases anesthetics; and vomiting, toxicity, surgery, 965 ing, 98 aminophylline; therapy, DUE criteria, 1033 ondansetron hydrochloride; and vomiting, therapy, United Kingdom suspends sales of triazolam; FDA to theophylline; therapy, DUE criteria, 1033 cisplatin toxicity, 1026 review safety data, 9 Nebacumab Upcoming Specialty Meetings, 9, 103, 221, 296, 385, sepsis; antiendotoxin monoclonal antibodies, therapy, 470, 576, 670, 750, 912, 1000 criteria, 255 Warnings about use of angiotensin-converting-en- use; evaluation, criteria, 257 zyme inhibitors in advanced pregnancy strength- Neoplasms; pamidronate disodium; hypercalcemia ened, 467 Macrolides therapy, FDA approvals, 220 Working group issues report on aluminum contami- azithromycin; FDA approvals, 98; marketing delay, News, 4, 96, 208, 287, 378, 458, 574, 669, 747, 825, 912, 991 nation of parenteral nutrient solutions, 6 Pfizer, 218; pharmacology, 137 Acellular pertussis vaccine approved by FDA, 290 Zalcitabine approved under accelerated drug review clarithromycin; FDA approvals, 98; pharmacology, Adverse effects prompt withdrawal of temafloxacin, policy, 747 137 747 Nimodipine; cerebrovascular disorders; ischemic erythromycin; gastroparesis therapy, effects, motilin, Benzodiazepine antagonist approved by FDA, 287 stroke therapy, 350 917 Call for applications to conduct research on patient Nutrition Magnesium sulfate; eclampsia; and preeclampsia ther- outcomes associated with pharmaceuticai therapy diet; lactose intolerance, lactase effects, reduced apy, 236 in ambulatory-care setting, 467 symptoms, 533 Marketing CDC advises on management of persons exposed to parenteral; home therapy, side effects, 543 aldesleukin; FDA approvals, 669 multiple-drug-resistant tuberculosis, 991 azithromycin; delay, Pfizer, 218; FDA approvals, 98 Cefpodoxime marketing approved by FDA, 999 cefpodoxime proxetil; FDA approvals, 999 Cefprozil enters oral antibiotic market, 295 Oo cefprozil; FDA approvals, 295 Cognitive enhancers illegal, says FDA, 467 clarithromycin; FDA approvals, 98 Depression in elderly is common but undertreated, cognition activators; FDA disapprovals, 467 says expert panel, 96 Occult blood; tests, laboratory; Gastroccult vs. Hemoc- diphtheria and tetanus toxoids and pertussis vac- Didanosine and foscarnet marketed for use by pa- cult, interference, sucralfate, 625 cines; FDA approvals, 290 tients with AIDS, 4 Olsalazine sodium; inflammatory bowel disease; thera- felodipine; FDA approvals, 9 EPA seeks information on efficacy of sterilants and py, 514 finasteride; FDA approvals, 825 disinfectants, 295 Omeprazole flumazenil; FDA approvals, 287 Expert panel issues guidelines on asthma manage- ulcers; therapy, NSAID toxicity, review, 690 lomefloxacin hydrochloride; FDA approvals, 458 ment, 295 use; evaluation, criteria, 177 nabumetone; FDA approvals, 381 False-positive viral antibody test results reported in Ondansetron hydrochloride; pharmacokinetics; thera- new drugs; and biologicals, FDA approvals, 1991, 208 influenza vaccine recipients, 220 py, cisplatin toxicity, 1026 pamidronate disodium; FDA approvals, 220 FDA announces four initiatives for drug approval Opiates; pain; protocols, therapy, 391 pravastatin sodium; FDA approvals, 99 system, 574 Osteoarthritis quinapril hydrochloride; FDA approvals, 220 FDA approves release of recombinant interleukin-2 nabumetone; therapy, FDA approvals, 381 sertraline hydrochloride; FDA approvals, 381 product, 669 oxaprozin; therapy, 591 simvastatin; FDA approvals, 290 FDA approves treatment IND protocol for taxol, 912 Ovarian neoplasms; taxol; treatment IND, FDA ap- temafloxacin hydrochloride; FDA approvals, 381 FDA seeks changes in benzodiazepine packaging and provals, 912 ticlopidine hydrochloride; FDA approvals, 99 labeling, 295 Oxaprozin; arthritis; rheumatoid, and osteoarthritis, zalcitabine; FDA approvals, accelerated drug review FDA seizes cold sterilizing solution, 220 therapy, 591 policy, 747 FDA warns of overdose risk from dosage cups, 220 Mechanism of action FDA warns quality of underground zalcitabine is P antibiotics; postantibiotic effect, 865 poor; Roche expands premarketing access pro- azithromycin, 137 grams, 385 clarithromycin, 137 Federal task force revises recommendations for PCP idarubicin, 152 prophylaxis, 670 Package inserts; patients; triazolam, changes, FDA ap- lomefloxacin hydrochloride; review, 753 Felodipine marketed as antihypertensive agent, 9 provals, 467 sertraline hydrochloride, 381 Finasteride approved for treatment of benign prostat- Paclitaxel, see Taxol sumatriptan succinate; migraine therapy, review, 919 ic hyperplasia, 825 Pain temafloxacin hydrochloride; review, 753 Free drug programs for indigent patients should be analgesics; protocols, therapy, 309 ticlopidine hydrochloride; cerebrovascular disorders more accessible, says Senate committee on aging, lidocaine, combination, prilocaine; anesthesia, s.c. in- therapy, review, 603 1000 jection sites, 347 Mesalamine; inflammatory bowel disease; therapy, 514 Guidelines address systemic glucocorticosteroid use morphine sulfate; postoperative, Baxter Infusor PCA, Methemoglobinemia; dapsone; toxicity, therapy, 800 for infection management, 295 342; postoperative, intrathecal and i.v. PCA vs Methotrexate; pregnancy; ectopic, therapy, 529 HDL testing should be routine part of assessments of PCA alone, 958 Methylene blue; and charcoal activated; therapy, dap- coronary heart disease risk, says consensus panel, therapy; protocols, 391 sone toxicity, 800 378 Pamidronate disodium; marketing; FDA approvals, Metoclopramide hydrochloride; pharmacokinetics; Heavy use of inhaled B agonists associated with in- 220 Vol 11 Dec 1992 Clinical Pharmacy 1047 Annual Index Pancuronium bromide; use; evaluation, criteria, 435 pamidronate disodium, 220 beractant; DUE criteria, 357 Parasympatholytic agents; drug use; evaluation, crite- pravastatin sodium, 99; hypercholesterolemia thera- didanosine; DUE criteria, 885 ria, therapy, extrapyramidal side effects, 553 py, review, 677 electrolytes, combination, polyethylene glycol; gastric Parenterals, see Injections quinapril hydrochloride, 220 lavage, diabetes mellitus, 751 Paroxetine; depression; therapy, review, 930 serotonin reuptake inhibitors; depression, therapy 506C80; P. carinii pneumonia, treatment IND, FDA Patches transdermal review, 930 approvals, 99 fentanyl; adverse reactions, diffuse rash, 222; pain sertraline hydrochloride, 381 omeprazole; ulcers, peptic esophagitis, therapy, DUI therapy, 22 simvastatin, 290 criteria, 177 scopolamine; hyperemesis gravidarum therapy, 830 sumatriptan succinate; migraine therapy, review, 919 pain; therapy, 309, 391 Patient-controlled analgesia; morphine sulfate; and in- temafloxacin hydrochloride, 381; review, 753 parasympatholytic agents; DUE criteria, therapy, ex- trathecal vs. PCA alone, postoperative pain therapy ticlopidine hydrochloride, 99; review, 603 trapyramidal side effects, 553 958; Baxter Infusor, postoperative pain therapy, 342 verapamil hydrochloride; equivalency, intact cap- skeletal muscle relaxants; DUE criteria, 435 Patients sules vs. sprinkled on food, 539 sumatriptan; DUE criteria, 972 inpatients; amphotericin B, DUE criteria, 809; antien- Pharmacy, institutional, hospital taxol; treatment IND, FDA approvals, 912 dotoxin monoclonal antibodies, DUE criteria, 257 quality assurance; programs, adenosine, DUE criteria, theophylline; DUE criteria, 1033 DUE criteria, therapy, extrapyramidal side effects programs, aminophylline, theophylline, DUE zidovudine; DUE criteria, 63 553; omeprazole, DUE criteria, 177; zidovudine, criteria, 1033; programs, amphotericin B, DUE cri- Pruritus; ursodiol; therapy, biliary cirrhosis, 672 DUE criteria, 63 teria, 809; programs, antiendotoxin monoclonal an- Psychotherapeutic agents outpatients; aminophylline, theophylline, DUE crite- tibodies, DUE criteria, 257; programs, beractant, toxicity; extrapyramidal side effects, therapy, DUE ria, 1033; DUE criteria, therapy, extrapyramidal DUE criteria, 357; programs, didanosine, DUE cri- criteria, 553 side effects, 553; omeprazole, DUE criteria, 177 teria, 885; programs, DUE c riteria, therapy, extra- toxicity; hyperprolactinemia, therapy, 851 sumatriptan, DUE criteria, 972; zidovudine, DUE pyramidal side effects, 5553 ; programs, Exosurf Pulmonary surfactants criteria, 63 Neonatal, DUE criteria, 355; programs, ome- alcohols, cetyl, combination, colfosceril palmitate, Pediatrics prazole, DUE criteria, 177; programs, skeletal mus- tyloxapol; adult respiratory distress syndrome amphotericin B; candidiasis therapy, burns, infant, cle relaxants, DUE criteria, 435; Fp rograms therapy, neonate, 880; DUE criteria, 355 883 sumatriptan DUE criteria, 972; programs, zidovu- beractant; DUE criteria, 357 analgesics and antipyretics; fever therapy, review dine, DUE criteria, 63 Purchasing; zalcitabine; quality problems, AIDS buyers 1005 Phenobarbital; and ethosuximide; clearance, peritoneal groups, 385 antibodies; monoclonal antiendotoxin, DUE criteria, 257 dialysis, 1030 antihistamines; DUE criteria, therapy, extrapyrami- Phenylpropanolamine hydrochloride; toxicity; hyper- Q dal side effects, 553 tension, lack, 168 antiparkinson agents; DUE criteria, therapy, extrapy- Phenytoin; eclampsia; and preeclampsia therapy, 236 ramidal side effects, 553 Pipecuronium bromide; use; evaluation, criteria, 435 benzodiazepines; DUE criteria, therapy, extrapyrami- Placental transfer; scopolamine; transdermal patches, Quality assurance; hospital pharmacy; programs, aden- dal side effects, 553 hyperemesis gravidarum therapy, 830 osine, DUE criteria, 727; programs, aminophylline, ceftriaxone; i.m., concentrated, pharmacokinetics, Plants; herbs; cognition disorders therapy, FDA disap- theophylline, DUE criteria, 1033; programs, ampho- toxicity, 961 provals, 467 tericin B, DUE criteria, 809; programs, antiendotoxin didanosine; DUE criteria, 885 Platelet aggregation inhibitors monoclonal antibodies, DUE criteria, 257; programs, diphtheria and tetanus toxoids and pertussis vac- hyperfibrinogenemia; therapy, 968 beractant, DUE criteria, 357; programs, didanosine, cines; marketing, FDA approvals, 290 ticlopidine hydrochloride; cerebrovascular disorders DUE criteria, 885; programs, DUE criteria, therapy, ethosuximide and phenobarbital; clearance, peritone- therapy, review, 603 extrapyramidal side effects, 553; programs, Exosurf al dialysis, 1030 Pneumonia; 566C80; P. carinii, treatment IND, FDA ap- Neonatal, DUE criteria, 355; programs, omeprazole, fluconazole; candidiasis therapy, lack, burns, infant, provals, 99 DUE criteria, 177; programs, skeletal muscle relax- 883 Poisoning; dapsone; therapy, 800 ants, DUE criteria, 435; programs, sumatriptan DUE Haemophilus b oligosaccharide conjugate vaccines Polyethylene glycol; combination, electrolytes; gastric criteria, 972; programs, zidovudine, DUE criteria, 63 equivalency, immunogenicity, 332 lavage, diabetes mellitus, protocols, 751 Quinapril hydrochloride; marketing; FDA approvals, Haemophilus b polysaccharide conjugate vaccines; Pravastatin sodium 220 equivalency, immunogenicity, 332 hypercholesterolemia; therapy, review, 677 Quinolones neonates; beractant, DUE criteria, ; ciprofloxacin marketing; FDA approvals, 99 ciprofloxacin hydrochloride; blood and milk levels, blood levels, maternal administration, 352; Exosurf Preeclampsia; therapy, 236 352 Neonatal, DUE criteria, 355; pulmonary surfactant, Pregnancy lomefloxacin hydrochloride; FDA approvals, 458; adult respiratory distress syndrome therapy, 880 angiotensin-converting enzyme inhibitors; risks, la- pharmacology, review, 753 pain; therapy, protocols, infants and neonates, 391 beling, warnings, 467 temafloxacin hydrochloride; FDA approvals, 381; parasympatholytic agents; DUE criteria, therapy, ex- methotrexate; ectopic, therapy, 529 pharmacology, review, 753; product withdrawal, trapyramidal side effects, 553 scopolamine; hyperemesis gravidarum therapy, toxicity, FDA regulations, 747 phenobarbital and ethosuximide; clearance, peritone- transdermal patches, 830 al dialysis, 1030 Prilocaine; combination, lidocaine; anesihesia, pain, s.c R zidovudine; DUE criteria, 63 injection sites, 347 Pfizer Pharmaceuticals; azithromycin; marketing de- Product withdrawal lay, 218 azithromycin; Pfizer, marketing delay, 218 Pharmacokinetics temafloxacin hydrochloride; toxicity, FDA regula- Rabies; immunization; vaccines, human rabies immune acetaminophen; fever therapy, pediatrics, review tions, 747 globulin, 37 1005 triazolam; United Kingdom, 9 Rabies immune globulin; immunization, 37 aldesleukin, 669 Prolactin inhibitors Rabies vaccines; human diploid cell; immunization, 37 anti-infective agents; absorption, intraperitoneal amantadine; hyperprolactinemia therapy, psycho- Rational therapy; antiarrhythmic agents, 714 CAPD, 246 tropic toxicity, 851 Regulations aspirin; fever therapy, pediatrics, review, 1005 bromocriptine; hyperprolactinemia therapy, psycho- Food and Drug Administration; astemizole, terfena- azithromycin, 98, 137 tropic toxicity, 851 dine, warning labels, cardiovascular toxicity, 825; cefpodoxime proxetil, 999 Propranolol; gastrointestinal hemorrhage; prophylaxis cognition activator marketing, 467; zalcitabine cefprozil, 295 cirrhosis, esophageal varices, 337 quality problems, premarketing access, 385 ceftriaxone; i.m., concentrated pediatrics, 961 Prostatic hypertrophy; finasteride; therapy, FDA ap- labeling; ACE inhibitors, warnings, risks, pregnancy, clarithromycin, 98, 137 provals, 825 467 didanosine, 4 Prothrombin time new-drug applications; approvals, changes, FDA pro- diphtheria and tetanus toxoids and pertussis vac- tetracycline hydrochloride; interactions, warfarin, po- cessing, 574 cines; pediatrics, 290 tentiation, 806 temafloxacin hydrochloride; product withdrawal, doxazosin mesylate; review, 415 warfarin sodium; interactions, tetracycline, potentia- FDA, 747 felodipine, 9 tion, 806 Respiratory distress syndrome fentanyl; transdermal patches, pain therapy Protocols alcohols, cetyl, combination, colfosceril palmitate, finasteride, 825 adenosine; DUE criteria, 727 tyloxapol; adult, therapy, neonate, 880; therapy, flumazenil, 287 alcohols, cetyl, combination, colfosceril palmitate, DUE criteria, 355 foscarnet sodium, 4 tyloxapol; DUE criteria, 355 beractant; therapy, DUE criteria, 357 ibuprofen; fever therapy, pediatrics, review, 1005 American Society of Hospital Pharmacists; antimicro- Respiratory smooth-muscle relaxants idarubicin, 152 bial prophylaxis, surgery, 483; globulin immune, aminophylline; availability, enteral administration, yinterferon; review, 834 iv. therapy, 117 428; DUE criteria, 1033 interferon gamma-1b; review, 834 aminophylline; DUE criteria, 1033 theophylline; DUE criteria, 1033 lomefloxacin hydrochloride, 458; review, 7 53 amphotericin B; bladder irrigation, DUE criteria, 809 Respiratory tract infections mesalamine, 514 antibodies; monoclonal antiendotoxin, DUE criteria, azithromycin; therapy, FDA approvals, 98; therapy, metoclopramide hydrochloride; peritoneal dialysis, 257 marketing delay, Pfizer, 218 174 antihistamines; DUE criteria, therapy, extrapyrami- clarithromycin; therapy, FDA approvals, 98 nabumetone, 381 dal side effects, 5 Reye’s syndrome; aspirin; toxicity, fever therapy, pedi- olsalazine sodium, 514 antiparkinson agents; DUE criteria, therapy, extrapy- atrics, 1005 ondansetron hydrochloride; therapy, cisplatin toxici ramidal side effects, 553 Roentgenographic agents; ionic; epidural, toxicity, in- ty, 1026 benzodiazepines; DUE criteria, therapy, extrapyrami- advertent intrathecal injection, 105 oxaprozin, 591 dal side effects, 553 1048 Clinical Pharmacy Vol11 Dec 1992 Annual Index Ss occult blood; Gastroccult vs. Hemoccult, interference, side effects, pediatric sucralfate, 625 Haemophilus b polysaccharide conjugate vaccines; side Tetracycline hydrochloride; interactions; warfarin, po- effects, pediatrics, 332 Sales; triazolam; product withdrawal, United King- tentiation, prothrombin time, 806 heparin; flushes, thrombocytopenia, thromboembo- dom, 9 Tetracyclines; tetracycline hydrochloride; interactions, lism, 797 Saline, see Sodium chloride warfarin, potentiation, prothrombin time, 806 ibuprofen; fever therapy, pediatrics, review, 1005 Scopolamine; hyperemesis gravidarum; transdermal Theophylline idarubicin; side effects, 152 patches, 830 blood levels; aminophylline availability, enteral ad- injections; pain, lidocaine—prilocaine topical anesthe- Seizures; cefazolin sodium; toxicity, intraventricular in- ministration, 428 sia, 347 jections, 104 use; evaluation, criteria, 1033 y-interferon; side effects, review, 834 Self-study Materials; Concepts in Oncology Therapeutics, Therapy Consultation, 672, 751, 830, 917 interferon gamma-1b; side effects, review, 834 4 Self-Instructional Course, 568 Diabetes control during bowel cleansing with PEG- lomefloxacin hydrochloride; side effects, 458, 753 Sepsis; antibodies; antiendotoxin monoclonal, therapy, electrolyte solution, 751 mesalamine; side effects, 514 223; antiendotoxin monoclonal, therapy, criteria, 255 Erythromycin, motilin, and gastroparesis, 917 methotrexate; side effects, ectopic pregnancy therapy, antiendotoxin monoclonal, therapy, DUE criteria, Transdermal scopolamine for hyperemesis gravidar- 529 Serotonin agonists um, 830 morphine sulfate; Baxter Infusor, PCA, postoperative sumatriptan; DUE criteria, 972 Use of ursodiol in a patient with biliary cirrhosis, 672 pain therapy, 342; muscle spasticity, midazolam sumatriptan succinate; migraine therapy, review, 919 Thrombocytopenia; heparin; toxicity, i.v. lock flushing, therapy, 57; side effects, intrathecal and i.v. PCA vs. Sertraline hydrochloride 797 PCA alone, 958 depression; therapy, review, 930 Thromboembolism; heparin; toxicity, i.v. lock flushing, nabumetone, 381 marketing; FDA approvals, 381 797 nutrition; parenteral, home therapy, 543 Shock; antibodies; septic, antiendotoxin monoclonal, Ticlopidine hydrochloride olsalazine sodium; side effects, 514 therapy, 223 cerebrovascular disorders; therapy, review, 603 omeprazole; side effects, DUE criteria, 177 Simvastatin; marketing; FDA approvals, 290 marketing; FDA approvals, 99 oxaprozin; side effects, 591 Skeletal muscle relaxants Topical preparations pamidronate disodium, 220 atracurium besylate; DUE criteria, 435 fentanyl; transdermal patches, pain therapy, 22 parasympatholytic agents; DUE criteria, therapy, ex- doxacurium chloride; DUE criteria, 435 lidocaine, combination, prilocaine; creams, anesthe- trapyramidal side effects, 553 metocurine iodide; DUE criteria, 435 sia, pain, s.c. injection sites, 347 phenylpropanolamine hydrochloride; hypertension, midazolam hydrochloride; muscle spasticity therapy, Toxicity lack, 168 morphine toxicity, 57 acetaminophen; fever therapy, pediatrics, review, pravastatin sodium; side effects, 99; side effects, hy- pancuronium bromide; DUE criteria, 435 1005 percholesterolemia therapy, review, 677 pipecuronium bromide; DUE criteria, 435 adenosine; DUE criteria, 727 psychotherapeutic agents; extrapyramidal side ef- tubocurarine chloride; DUE criteria, 435 6 agonists; regular vs. as-needed, asthma, 877 fects, therapy, DUE criteria, 553; hyperprolactine- vecuronium bromide; DUE criteria, 435 alcohols, cetyl, combination, colfosceril palmitate, mia, therapy, 851 Skin diseases tyloxapol; DUE criteria, 355 quinapril hydrochloride, 220 azithromycin; therapy, FDA approvals, 98 aldesleukin, 669 roentgenographic agents; ionic, inadvertent intrathe- clarithromycin; FDA approvals, 98 aminophylline; DUE criteria, 1033 cal injection, 105 Sodium chloride; comparison, heparin; i.v. lock flush- amphotericin B; DUE criteria, 809 scopolamine; placental transfer, hyperemesis gravi- ing, 797 anesthetics; nausea and vomiting, abdominal surgery, darum transdermal therapy, 830 Sucralfate 965 serotonin reuptake inhibitors; side effects, depression interference; occult blood tests, Gastroccult vs. He- angiotensin-converting enzyme inhibitors; pregnan- therapy, review, 930 moccult, 625 cy, labeling, warnings, 467 sertraline hydrochloride, 381 toxicity; aluminum overload, deferoxamine therapy, antiarrhythmic agents, 714; interactions, implanted simvastatin, 290 CAPD, 636 cardiac devices, 48 skeletal muscle relaxants; DUE criteria, 435 Sumatriptan; use; evaluation, criteria, 972 antibodies; monoclonal antiendotoxin, DUE criteria, 257 sucralfate; aluminum overload, deferoxamine thera- Sumatriptan succinate; migraine; therapy, review, 919 anticoagulants; hemorrhage, dental surgery, 857 py, CAPD, 636 Surgery antihistamines; DUE criteria, therapy, extrapyrami- sumatriptan; DUE criteria, 972 anesthetics; abdominal, toxicity, nausea and vomit- dal side effects, 553 sumatriptan succinate; side effects, migraine therapy, ing, 965 anti-infective agents; postantibiotic effect, factors, 865 review, 919 anti-infective agents; prophylaxis, ASHP protocols, anti-inflammatory agents; nonsteroidal, ulcers, thera- temafloxacin hydrochloride, 381; side effects, 753 483 py, review, 690 terfenadine; cardiovascular, labeling, warnings, 825 dental; hemorrhage prophylaxis, anticoagulant toxici- antiparkinson agents; DUE criteria, therapy, extrapy- tetracycline hydrochloride; interactions, warfarin, po- ty, 857 ramidal side effects, 553 tentiation, prothrombin time, 806 protocols; pain therapy, 309, 391 aspirin; Reye’s syndrome, fever therapy, pediatrics, theophylline; DUE criteria, 1033 Sustained-action medications 1005 ticlopidine hydrochloride; side effects, 99; side effects, calcium antagonists; therapy, improved patient com- astemizole; cardiovascular, labeling, warnings, 825 review, 603 pliance, 549 azithromycin; side effects, 98, 137; side effects, mar- triazolam; side effects, product withdrawal, United verapamil hydrochloride; intact capsules vs. sprin- keting delay, Pfizer, 218 Kingdom, 9 kled on food, pharmacokinetics, 539 benzodiazepines; DUE criteria, therapy, extrapyrami- verapamil hydrochloride; side effects, lack, intact cap- Sympatholytic agents dal side effects, 553; overdose, flumazenil therapy sules vs. sprinkled on food, 539 6 blockers; hyperfibrinogenemia therapy, 968 287 warfarin sodium; interactions, tetracycline, potentia- nadolol; gastrointestinal hemorrhage, prophylaxis, beractant; DUE criteria, 357 tion, prothrombin time, 806; intramural hematoma cirrhosis, esophageal varices, 337 fs blockers; side effects, gastrointestinal hemorrhage of the small intestine, 632 propranolol; gastrointestinal hemorrhage, prophylax- prophylaxis, 337 zalcitabine, 747 is, cirrhosis, esophageal varices, 337 calcium antagonists; side effects, 549 zidovudine; DUE criteria, 63 Sympathomimetic agents cefazolin sodium; seizures, intraventricular injec- Tranexamic acid; hemorrhage; prophylaxis, dental sur- § agonists; aerosols, dosage schedules, asthma thera- tions, 104 gery, anticoagulant toxicity, py, 877; asthma therapy, controversies, 13 cefpodoxime proxetil, 999 Transplantation; bone marrow; adult acute leukemia, phenylpropanolamine hydrochloride; toxicity, hyper- cefprozil, 295 therapy, review, 767; globulin immune, concentrated tension, lack, 168 ceftriaxone; side effects, lack, i.m., concentrated, pedi- injections, toxicity, 1022 atrics, 961 Triazolam T cisplatin; ondansetron therapy, pharmacokinetics, labeling; changes, FDA approvals, 467 1026 product withdrawal; United Kingdom, 9 clarithromycin; side effects, 98, 137 Tubocurarine chloride; use; evaluation, criteria, 435 dapsone; hemolytic anemia, methemoglobinemia, Tyloxapol; combination, alcohols, cetyl, colfosceril Tachycardia; adenosine; paroxysmal supraventricular, therapy, 800 palmitate; adult respiratory distress syndrome thera- therapy, DUE criteria, 727 didanosine, 4; DUE criteria, 885 py, neonate, 880; use evaluation criteria, 355 Taxol; ovarian neoplasms; treatment IND, FDA approv- diphtheria and tetanus toxoids and pertussis vac- als, 912 cines; side effects, pediatrics, 290 U Temafloxacin hydrochloride doxazosin mesylate; side effects, 415 marketing; FDA approvals, 381 drugs; endocrine disorders, HIV infections, therapy, pharmacology; review, 753 705; measuring cups, spoons, droppers, dosing product withdrawal; toxicity, FDA regulations, 747 problems, 220 Ulcers Teratogenicity felodipine, 9 anti-inflammatory agents; nonsteroidal, toxicity, re- angiotensin-converting enzyme inhibitors; pregnan- fentanyl; transdermal, side effects, 22 view, 690 cy, labeling, warnings, 467 finasteride, 825 omeprazole; duodenal, gastric, therapy, DUE criteria, scopolamine; placental transfer, hyperemesis gravi- fiumazenil, 287 177 darum transdermal therapy, 830 foscarnet sodium, 4 United Kingdom; triazolam; product withdrawal, 9 Terfenadine; toxicity; cardiovascular, labeling, warn- ganciclovir; liver, cytomegalic inclusion disease ther- Urinary tract infections; amphotericin B; therapy, DUE ings, 825 apy, AIDS, 432 criteria, 809 Tests, laboratory globulin immune; reconstitution, dextrose vs. water Ursodiol; pruritus; therapy, biliary cirrhosis, 672 cholesterol; and HDL monitoring, coronary disease, for injection, lack, 628; side effects, concentrated 378 injections, 1022 Haemophilus b oligosaccharide conjugate vaccines; Vol 11 Dec 1992 Clinical Pharmacy 1049 Annual Index Vv Vitamins; marketing; cognition disorders therapy, FDA X disapprovals, 467 Volume of distribution, see Drugs, body distribution Vaccines Vomiting Xomen-E5 diphtheria and tetanus toxoids and pertussis; market- anesthetics; and nausea, toxicity, surgery, 965 sepsis; antiendotoxin monoclonal antibodies, therapy, ing, FDA approvals, 290 ondansetron hydrochloride; and nausea, therapy, cis- 223; antiendotoxin monoclonal antibodies, therapy, Haemophilus b oligosaccharide conjugate; equivalen- platin toxicity, 1026 criteria, 255 cy, immunogenicity, pediatrics, 332 use; evaluation, criteria, 257 Haemophilus b polysaccharide conjugate; equivalency, Ww immunogenicity, pediatrics, 332 Z rabies; human diploid cell, immunization, 37 Vancomycin; intraperitoneal; absorption, CAPD, 246 Vasodilating agents; hyperfibrinogenemia; therapy, Warfarin sodium 968 interactions; tetracycline, potentiation, prothrombin Zalcitabine Vecuronium bromide; use; evaluation, criteria, 435 time, 806 marketing; FDA approvals, accelerated drug review Vehicles toxicity; intramural hematoma of the small intestine, policy, 747 dextrose, comparison, water for injection; globulin 632 purchasing; AIDS buyers groups, quality problems, immune reconstitution, toxicity, 628 Water for injection; comparison, dextrose; globulin im- 385 water for injection, comparison, dextrose; globulin mune reconstitution, toxicity, 628 Zidovudine immune reconstitution, toxicity, 628 Weight; patients; nausea and vomiting, anesthetics tox- and zalcitabine; HIV infections, combined therapy, Verapamil hydrochloride; pharmacokinetics; equiva- icity, surgery, 965 lency, intact capsules vs. sprinkled on food, 539 Wounds and injuries; protocols; pain therapy, 309, 391 use; evaluation, criteria, 63 Author Index A Cantral, Kimberly A. see Jungnickel, Paul W., 677 g Capparelli, Edmund V. New calcium-channel blockers. improved therapy? 549 Acosta, Mark A. see Bradley, John S., 961 Cersosimo, Robert J. Idarubicin: an anthracycline antin- Fankhauser, Martha P. Book review, 655 Adams, Margaret A. see Kozloski, Gary D., 539 eoplastic agent, 152 Figge, Helen L. Possible ganciclovir-induced hepato- Agency for Health Care Policy and Research Acute Chan, C. Y. Jennifer Colfosceril in an infant with adult toxicity in patients with AIDS, 432 pain management: operative or medical procedures respiratory distress syndrome, 880 Fisher, Joseph N. see Marken, Patricia A., 851 and trauma, part 1, 309; part 2, 391 Chandler, Mary H. H. see Parr, Michael D., 1026 Flynn, Patrice L. Topical capsaicin for osteoarthritis (let- Anderson, Douglas C. Jr. see Sagraves, Rosalie, 830 Chin, Barbara see Marquardt, Eric D., 1030 ter), 308 ASHP Commission on Therapeutics ASHP therapeutic Coleman, Cathy L. see Benson, John M., 965 Foster, Thomas S. see Wermeling, Daniel P., 342 guidelines for intravenous immune globulin, 117 Compogiannis, Lisa S. see Bradley, John S., 961 Frenia, Maureen L. Features and treatment of rabies, 37 ASHP Commission on Therapeutics ASHP therapeutic Coonce, Shannon L. Beta-adrenergic agonists in asthma guidelines on antimicrobial prophylaxis in surgery, (letter), 14 G 483 Coonce, Shannon L. see also Simon, Pamela A., 387 Avent, Minyon L. Warfarin-induced intramural hema- Corso, Diane M. see Calis, Karim Anton, 22 toma of the small intestine, 632 Corso, Diane M. see also Kohler, David R., 584 Cortese, Linda M. Criteria for use of didanosine in Gabbe, Steven G. see Gardner, Debra K., 352 adult and pediatric patients, 885 Gales, Barry J. see Segars, Larry W., 514 Cortese, Linda M. Potential interaction between terfe- Gardner, Debra K. Simultaneous concentrations of cip- nadine and macrolide antibiotics (letter), 675 rofloxacin in breast milk and in serum in mother and breast-fed infant, 352 Babamoto, Kenneth S. Doxazosin: a new «@,-adrenergic D Garrelts, James C. White clot syndrome and thrombo- antagonist, 415 cytopenia: reasons to abandon heparin i.v. lock flush Bagwell, J. Todd see Martin, Emory S. III, 104 solution, 797 Bailie, George R. see Figge, Helen L., 432 Golembiewski, Julie A. see Donnelly, Andrew J., 435 Banner, William Jr. Use of succimer (letter), 388 Danos, Erica A. Apparent potentiation of warfarin ac- Goodwin, S. Diane Criteria for use of zidovudine in Barone, Joseph A. see Frenia, Maureen L., 37 tivity by tetracycline, 806 adult and pediatric inpatients and outpatients, 63 Barriere, Steven L. Gram-negative sepsis, the sepsis Danziger, Larry H. see Piscitelli, Stephen C., 137 Gora, Mary Lea Pharmacokinetics of intraperitoneal syndrome, and the role of antiendotoxin monoclonal Darbinian, Jeanne A. see Herfindal, Eric T., 543 metoclopramide in a patient with renal failure, 174 antibodies, 223 D’Elia, John A. see Min, David I., 636 Greene, Stan A. see Wermeling, Daniel P., 342 Barton, Terri L. see Chan, C. Y. Jennifer, 880 De Vito, Joseph M. see Kozloski, Gary D., 539 Grimsley, Sara R. Paroxetine, sertraline, and fluvoxam- Batra, Kumar K. see Marquardt, Eric D., 1030 DeVane, C. Lindsay Book review, 277 ine: new selective serotonin reuptake inhibitors, 930 Bauman, Jerry L. see Tworek, Deborah A., 48 DiPiro, Joseph T. see Benson, John M., 965 Guglielmo, B. Joseph see Barriere, Steven L., 223 Bay, William see Gora, Mary Lea, 174 DiPiro, Joseph T. see also Hardin, Thomas C., 255 Benssurogne,r y,J oh9n6 5 M. Nausea and vomiting after abdominal Donbnreolmliyd,e , Avnedcruerwo niJu. mC ritberroimai defo,r uaster acofu ripuamn cubresoynliautem, H Bernstein, Linda R. see Herfindal, Eric T., 543 tubocurarine chloride, metocurine iodide, pipecuro- Bezarro, Edward R. see Wermeling, Daniel P., 342 nium bromide, and doxacurium chloride in adults, Bhatt-Mehta, Varsha Criteria for use of colfosceril (Exo- 435 Haas, Curtis E. Book review, 565 surf Neonatal) in neonates, 355 Donnigan, L. Deane see Benson, John M., 965 Hardin, Thomas C. Who should receive antiendotoxin Birmingham, William E. see Littrell, Robert A., 57 Drwal-Klein, Laureen A. Antipyretic therapy in the monoclonal antibody therapy? (editorial), 255 Bjornson, Darrel C. see Cortese, Linda M., 675, 885 febrile child, 1005 Harter, Chris see Gardner, Debra K., 352 Blake, Kathryn V. see Hill, Malcolm R., 877 Haykal, Radwan F. see Marken, Patricia A., 851 Bolinger, Ann M. Recombinant interferon gamma for E Healy, Daniel P. Book review, 900 treatment of chronic granulomatous disease and other Hecker, Earl T. see Wetmore, Robert W., 958 disorders, 834 Henderson, Lisa M. see Parr, Michael D., 1026 Boucher, Bradley A. see Wermeling, Daniel P., 342 Herfindal, Eric T. Complications of home parenteral Bowden, Talmadge A. Jr. see Benson, John M., 965 Ebert, Steven C. Characterization of the postantibiotic nutrition, 543 Bradley, John S. Pharmacokinetics and safety of intra- effect, 876 Herzfeld, Jeff see Nee, Chris, 13 muscular injection of concentrated ceftriaxone in chil- Elder, Cheryl A. B-Adrenergic antagonists for primary Hill, Malcolm R. Regularly scheduled versus as-needed dren, 961 prevention of gastrointestinal hemorrhage in patients use of inhaled B agonists in the treatment of asthma, Briceland, Laurie L. see Figge, Helen L., 432 with cirrhosis and esophageal varices, 337 877 Briggs, Gerald G. see Wermeling, Daniel P., 342 Ernst, Edzard Lowering the plasma fibrinogen concen- Hirokawa, William T. see Babamoto, Kenneth S., 415 Brocavich, Joseph M. see Etzel, Joseph V., 705 tration with drugs, 968 Hirsch, Jan D. see Benson, John M., 965 Bush-Veith, Stacie see Martin, Emory S. III, 104 Ernst, Edzard Treating ischemic stroke: is nimodipine Hogue, Valerie W. see Herfindal, Eric T., 543 the answer? 350 Holman, Jonathan S. Influence of sucralfate on the de- Erstad, Brian L. Dapsone-induced methemoglobinemia tection of occult blood in simulated gastric fluid by Cc and hemolytic anemia, 800 two screening tests, 625 Etzel, Joseph V. Endocrine complications associated Holmes, Gregory B. see Kozloski, Gary D., 539 with human immunodeficiency virus infection, 705 Hsu, Van Doren Criteria for use of sumatriptan in adult Calis, Karim Anton Transdermally administered fenta- Ezell, Jeanne R. see Marken, Patricia A., 553 inpatients and outpatients, 972 nyl for pain management, 22 Ezri, Marilyn see Tworek, Deborah A., 48 Hsu, Van Doren Sumatriptan: a new drug for vascular Calis, Karim A. see also Kohler, David R., 584 headache, 919 Calis, Karim Anton see also Yurkowski, Peter ]., 917 Huber, Steven see Ippoliti, Cindy, 1022 Canaday, Bruce R. see Avent, Minyon L., 632 Hunt, Thomas L. see Kozloski, Gary D., 539 1050 Clinical Pharmacy Vol11 Dec 1992 Annual Index 5% dextrose injection or sterile water for injection, 628 quiring mechanical ventilation, 428 Miller, Lucinda G. Oxaprozin: a once-daily nonsteroi- Shepherd, Michele F. Criteria for use of antiendotoxin dal anti-inflammatory drug, 591 monoclonal antibodies (HA-1A and E5) in adult and Ignoffo, Robert J. Self-study materials review, 568 Min, David I. Sucralfate-associated aluminum toxicity pediatric inpatients, 257 Ippoliti, Cindy Toxicity of rapidly infused concentrated in a patient with renal failure: treatment with deferox- Shields, Brenda see Gora, Mary Lea, 174 intravenous immune globulin, 1022 amine, 636 Shipp, Kenneth W. see Goodwin, S. Diane, 63 Ishisaka, Denis Y. see Marquardt, Eric D., 1030 Mirro, Robert see Prevost, Rebecca Rogers, 357 Shwed, Jill A. see Holman, Jonathan S., 625 Ito, Matthew K. Ticlopidine: a new platelet aggregation Montgomery, Patricia A. Criteria for use of amphoteri- Simon, Pamela A. Asthma in children (letter), 387 inhibitor, 603 cin B bladder irrigation in adult inpatients, 809 Simon, Pamela A. see also Coonce, Shannon L., 14 Morales, Enid Criteria for use of adenosine in adults Skupski, Richard see Donnelly, Andrew J., 435 with paroxysmal supraventricular tachycardia, 727 Slimowitz, Richard Book review, 565 J Mowatt-Larssen, Christine A. Working group issues Smith, Alden R. see Ito, Matthew K., 603 report on aluminum contamination of parenteral nu- Snydman, David R. Use of cytomegalovirus immune trient solutions (News), 6 globulin (letter), 674 Jacobson, Pamala A. see Montgomery, Patricia A., 809 Murphy, Christine M. see Coonce, Shannon L., 14 Spivey, J. Michael The postantibiotic effect, 865 Jann, Michael W. see Grimsley, Sara R., 930 Murphy, Christine M. see also Simon, Pamela A., 387 Stanfield, Johnny A. see Benson, John M., 965 Johnson, Jerry B. see Kozloski, Gary D., 539 Murray, William E. see Bradley, John S., 961 Stegman, Mary see Stoukides, Cheryl A., 222 Jones, Daniel W. see Sands, Charles D., 168 Stoukides, Cheryl A. Diffuse rash associated with Joubert, Dennis W. Value of transdermal fentany] (let- N transdermal fentanyl (letter), 222 ter), 584 Stovall, Thomas G. see Prevost, Rebecca Rogers, 529 Jung, Kyung M. see Sands, Charles D., 168 Sybert, John W. see Wetmore, Robert W., 958 Jungnickel, Paul W. Pravastatin: a new drug for the Symonds, William T. Lomefloxacin and temafloxacin: treatment of hypercholesterolemia, 677 Nazari, José see Tworek, Deborah A., 48 two new fluoroquinolone antimicrobials, 753 Nee, Chris Beta-adrenergic agonists in asthma (letter), 13 T K Nix, David E. see Symonds, William T., 753 Kalt, Mark A. see Wetmore, Robert W., 958 Taddio, Anna Effect of lidocaine—prilocaine cream on Kane, Bud J. Book review, 901 pain from subcutaneous injection, 347 Kennedy, L. Douglas see Littrell, Robert A., 57 Taeubel, Mary A. see Bolinger, Ann M., 834 Kim, Hyun Jong see Sands, Charles D., 168 O’Brien, Maureen A. Systemic absorption of intraperi- Tisdale, James E. Are antiarrhythmic drugs obsolete? Kohler, David R. Value of transdermal fentany] (letter), toneal antimicrobials in continuous ambulatory peri- 714 584 toneal dialysis, 246 Tisdale, James E. Book review, 277 Kohler, David R. see also Calis, Karim Anton, 22 Tolman, Keith G. see Sanders, Steven W., 533 Koren, Gideon see Taddio, Anna, 347 P Torre, Michael see Etzel, Joseph V., 705 Korones, Sheldon B. see Prevost, Rebecca Rogers, 357 Travers, John D. see Mann, Katherine V., 388 Kowalsky, Steven F. see Figge, Helen L., 432 Tsu, Gloria L. see Bradley, John S., 961 Kozloski, Gary D. Bioequivalence of verapamil hydro- Tweeddale, Martin G. see Shalansky, Karen F., 428 chloride extended-release pellet-filled capsules when Parr, Michael D. Pharmacokinetics of ondansetron in Tworek, Deborah A. Interference by antiarrhythmic opened and sprinkled on food and when swallowed patients receiving cisplatin therapy, 1026 agents with function of electrical cardiac devices, 48 intact, 539 Patterson, Larry E. Book review, 901 Kuhn, John G. see Kane, Bud J., 901 Phelps, Stephanie J. see Drwal-Klein, Laureen A., 1005 Phillips, Marjorie Shaw Criteria for use of theophylline (aminophylline) in inpatients and outpatients with L pulmonary disease, 1033 Pickworth, Kerry K. Long-term dobutamine therapy Ustad, Cristina see Shalansky, Karen F., 428 for refractory congestive heart failure, 618 LLaafjioni,e , SCuazraonlnien e MC.r itseeer iaF refnoir a,u seM aouf reoemenp rLa.z, o3l7e in adult Pinlsuso ni,n flJuuelnizaanen et ypBe. bN evwac cicnoantsiiodne,r a3t3i2o ns for Haemophi- Vv patients and outpatients, 177 Piscitelli, Stephen C. Clarithromycin and azithromy- Leak, W. David see Littrell, Robert A., 57 cin: new macrolide antibiotics, 137 Lee, Marisa L. see Ito, Matthew K., 603 Prevost, Rebecca Rogers Criteria for use of beractant Vance-Bryan, Kyle Book review, 742 Lehman, Mark E. see Wermeling, Daniel P., 342 (Survanta) in neonates, 357 Vaughan, Leigh M. see Shalansky, Karen F., 428 Lindley, Celeste Book review, 92 Prevost, Rebecca Rogers Methotrexate for treatment of Visconti, James A. see Gora, Mary Lea, 174 Ling, Frank W. see Prevost, Rebecca Rogers, 529 unruptured ectopic pregnancy, 529 Vondracek, Thomas G. Use of ursodiol in a patient with Littrell, Robert A. Muscle spasms associated with intrath- biliary cirrhosis (Therapy Consultation), 672 ecal morphine therapy: Treatment with midazolam, 57 WwW Rasch, Deborah K. see Chan, C. Y. Jennifer, 880 Reitberg, Donald P. see Sanders, Steven W., 533 Wasserman, Richard L. see Miller, Kenneth B., 628 MacDonald, John S. see Parr, Michael D., 1026 Renger, Harvey Jr. see Martin, Emory S. III, 104 Weart, C. Wayne see Pinson, Julianne B., 332 Maloley, Pierre A. see Jungnickel, Paul W., 677 Restino, Maryann S. Reynolds see Elder, Chery! A., Webb, Charles R. see Tisdale, James E., 714 Mann, Katherine V. Use of succimer (letter), 388 337 Weibert, Robert T. Oral anticoagulant therapy in pa- Marcus, Steven M. Use of succimer (letter), 387 Robieux, Isabelle see Taddio, Anna, 347 tients undergoing dental surgery, 857 Marken, Patricia A. Criteria for use of agents for extra- Rodvold, Keith A. see Piscitelli, Stephen C., 137 Wermeling, Daniel P. Multicenter evaluation of a pa- pyramidal adverse effects in adult, adolescent, and Ruck, Bruce see Marcus, Steven M., 387 tient-controlled analgesia device for the treatment of child inpatients and outpatients, 553 postoperative pain, 342 Marken, Patricia A. Management of psychotropic-in- Ss West, Dennis see Flynn, Patrice L., 308 duced hyperprolactinemia, 851 Wetmore, Robert W. Intrathecal administration of mor- Marquardt, Eric D. Removal of ethosuximide and phe- phine followed by patient-controlled intravenous ad- nobarbital by peritoneal dialysis in a child, 1030 ministration for postoperative analgesia, 958 Martin, Emory S. III Danger of epidural use of ionic Sagraves, Rosalie Transdermal scopolamine for hy- Williams, Dennis M. Asthma in children (letter), 386 contrast media (letter), 105 peremesis gravidarum (Therapy Consultation), 830 Williams, Loretta Ann see Ippoliti, Cindy, 1022 Martin, Emory S. III Seizures after intraventricular ce- Sahn, Steven A. see Shalansky, Karen F., 428 Wilson, Dean C. Fluconazole failure in a child with fazolin administration (letter), 104 Sanders, Steven W. Effect of a single dose of lactase on burns and candidemia, 883 Mason, Nancy A. see O’Brien, Maureen A., 246 symptoms and expired hydrogen after lactose chal- Wojtynek, Jeffrey E. see Donnelly, Andrew J., 435 Mauro, Laurie S. see Mauro, Vincent F., 897 lenge in lactose-intolerant subjects, 533 Wong, Alvin F. see Herfindal, Eric T., 543 Mauro, Vincent F. Book review, 897 Sands, Charles D. Effect of phenylpropanolamine hy- Woster, Patricia S. see Montgomery, Patricia A., 809 McCauley, Dayna L. Treatment of adult acute leuke- drochloride on blood pressure in Korean patients McmCioal,l a7m6,7 Patrick L. see Morales, Enid, 727 zwiidteh, 1h6y8p ertension controlled by hydrochlorothia- Y McCombs, Janet Treatment of preeclampsia and Sawyer, William T. see Avent, Minyon L., 632 eclampsia, 236 Schenkein, David P. see Miller, Kenneth B., 628 McIntyre, William J. see Parr, Michael D., 1026 Schoenbrun, Karen J. Book review, 373 Yurkowski, Peter J. Erythromycin, motilin, and gastro- McMahon, Teresa Diabetes control during bowel Schumacher, Robert E. see Bhatt-Mehta, Varsha, 355 paresis (Therapy Consultation), 917 cleansing with PEG-electrolyte solution (Therapy Segars, Larry W. Mesalamine and olsalazine: 5-ami- Consultation), 751 nosalicylic acid agents for the treatment of inflamma- Z Miller, Donald R. Treatment of nonsteroidal anti-in- tory bowel disease, 514 flammatory drug-induced gastropathy, 690 Seifert, Charles F. see Vondracek, Thomas G., 672 Miller, Kenneth B. Safety and tolerability of an intrave- Seth, Shiv see Gora, Mary Lea, 174 nous immune globulin at various concentrations in Shalansky, Karen F. Absolute bioavailability of amin- Zol5a8,3 Elizabeth M. Use of surfactant products (letter), ophylline liquid administered enterally in adults re- Vol 11 Dec 1992 Clinical Pharmacy 1051